These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 35319490)

  • 1. Thyroid dermopathy responds to teprotumumab therapy.
    Crespo-Trevino R; Schiffman J; Ugradar S; Cockerham K; Douglas R; de Leon-Garza D; Tang R
    Endocrinol Diabetes Metab Case Rep; 2022 Mar; 2022():. PubMed ID: 35319490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapid response of thyroid eye disease, peripheral edema, and acropathy to teprotumumab infusion.
    Kelly DA; Turbin RE
    Am J Ophthalmol Case Rep; 2024 Jun; 34():102031. PubMed ID: 38487336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Teprotumumab: A Review in Thyroid Eye Disease.
    Nie T; Lamb YN
    Drugs; 2022 Nov; 82(17):1663-1670. PubMed ID: 36418673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Teprotumumab in Thyroid Eye Disease.
    Teo HM; Smith TJ; Joseph SS
    Ther Clin Risk Manag; 2021; 17():1219-1230. PubMed ID: 34858025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Teprotumumab: Interpreting the Clinical Trials in the Context of Thyroid Eye Disease Pathogenesis and Current Therapies.
    Winn BJ; Kersten RC
    Ophthalmology; 2021 Nov; 128(11):1627-1651. PubMed ID: 33930408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Teprotumumab for Treatment of Pretibial Myxedema.
    Reyes MP; Cabrera J; Singh J; Turnbull D
    JCEM Case Rep; 2023 Jan; 1(1):luac037. PubMed ID: 37908268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Teprotumumab and the Evolving Therapeutic Landscape in Thyroid Eye Disease.
    Kossler AL; Douglas R; Dosiou C
    J Clin Endocrinol Metab; 2022 Aug; 107(Suppl_1):S36-S46. PubMed ID: 36346685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-Term Efficacy of Teprotumumab in Thyroid Eye Disease: Follow-Up Outcomes in Three Clinical Trials.
    Kahaly GJ; Subramanian PS; Conrad E; Holt RJ; Smith TJ
    Thyroid; 2024 Jul; 34(7):880-889. PubMed ID: 38824618
    [No Abstract]   [Full Text] [Related]  

  • 9. Teprotumumab for the Treatment of Recalcitrant Thyroid Eye Disease.
    Men CJ; Amarikwa L; Pham B; Sears C; Clauss K; Lee BW; Lee WW; Pasol J; Ugradar S; Shinder R; Cockerham K; Wester S; Douglas R; Kossler AL
    Ophthalmic Plast Reconstr Surg; 2024 May-Jun 01; 40(3):276-285. PubMed ID: 37972960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Refractory Thyroid Eye Disease Unresponsive to Teprotumumab: A Case Report.
    Singh G; Taylor B; Michalek S
    Cureus; 2023 Nov; 15(11):e48861. PubMed ID: 38111423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel teprotumumab treatment of severe thyroid dermopathy; ototoxicity as an adverse side effect.
    Patel RT; Grider DJ; Ramey N
    Dermatol Online J; 2023 Feb; 29(1):. PubMed ID: 37040908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Paradigm Shift in the Management of Thyroid Eye Disease How Teprotumumab Has Changed the Therapeutic Interface.
    Ugradar S; Kossler AL; Douglas R; Cockerham K
    J Neuroophthalmol; 2022 Mar; 42(1):26-34. PubMed ID: 35500236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expert Consensus on the Use of Teprotumumab for the Management of Thyroid Eye Disease Using a Modified-Delphi Approach.
    Douglas RS; Kossler AL; Abrams J; Briceño CA; Gay D; Harrison A; Lee M; Nguyen J; Joseph SS; Schlachter D; Tan J; Lynch J; Oliver L; Perry R; Ugradar S
    J Neuroophthalmol; 2022 Sep; 42(3):334-339. PubMed ID: 35421877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials.
    Kahaly GJ; Douglas RS; Holt RJ; Sile S; Smith TJ
    Lancet Diabetes Endocrinol; 2021 Jun; 9(6):360-372. PubMed ID: 33865501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and Exposure-Response Relationship of Teprotumumab, an Insulin-Like Growth Factor-1 Receptor-Blocking Antibody, in Thyroid Eye Disease.
    Xin Y; Xu F; Gao Y; Bhatt N; Chamberlain J; Sile S; Hammel S; Holt RJ; Ramanathan S
    Clin Pharmacokinet; 2021 Aug; 60(8):1029-1040. PubMed ID: 33768488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of hearing dysfunction in patients with Graves' disease and thyroid eye disease without or with teprotumumab.
    Smith TJ; Holt RJ; Fu Q; Qashqai A; Barretto N; Conrad E; Brant JA
    J Clin Endocrinol Metab; 2024 Aug; ():. PubMed ID: 39138817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Teprotumumab for the Treatment of Active Thyroid Eye Disease.
    Douglas RS; Kahaly GJ; Patel A; Sile S; Thompson EHZ; Perdok R; Fleming JC; Fowler BT; Marcocci C; Marinò M; Antonelli A; Dailey R; Harris GJ; Eckstein A; Schiffman J; Tang R; Nelson C; Salvi M; Wester S; Sherman JW; Vescio T; Holt RJ; Smith TJ
    N Engl J Med; 2020 Jan; 382(4):341-352. PubMed ID: 31971679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glycemic Trends in Patients with Thyroid Eye Disease Treated with Teprotumumab in 3 Clinical Trials.
    Smith TJ; Cavida D; Hsu K; Kim S; Fu Q; Barbesino G; Wester ST; Holt RJ; Bhattacharya RK
    Ophthalmology; 2024 Jul; 131(7):815-826. PubMed ID: 38253291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Objective Diplopia Outcomes for Patients Treated With Teprotumumab for Thyroid Eye Disease.
    Mudalegundi S; Huang P; Henderson AD; Carey AR
    J Neuroophthalmol; 2024 Mar; 44(1):80-86. PubMed ID: 38294416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Teprotumumab Efficacy, Safety, and Durability in Longer-Duration Thyroid Eye Disease and Re-treatment: OPTIC-X Study.
    Douglas RS; Kahaly GJ; Ugradar S; Elflein H; Ponto KA; Fowler BT; Dailey R; Harris GJ; Schiffman J; Tang R; Wester S; Jain AP; Marcocci C; Marinò M; Antonelli A; Eckstein A; Führer-Sakel D; Salvi M; Sile S; Francis-Sedlak M; Holt RJ; Smith TJ
    Ophthalmology; 2022 Apr; 129(4):438-449. PubMed ID: 34688699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.